We demonstrate here that 24% of advanced lung adenocarcinoma express high levels of mesothelin, and that high mesothelin expression is associated with EGFR wild-type and mutant KRAS and, independent of the mutation status, is associated with decreased overall survival. Here, KRAS is linked to lung adenocarcinoma.